245 related articles for article (PubMed ID: 27649629)
1. Allometry Is a Reasonable Choice in Pediatric Drug Development.
Liu T; Ghafoori P; Gobburu JV
J Clin Pharmacol; 2017 Apr; 57(4):469-475. PubMed ID: 27649629
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Drug Clearance in Premature and Mature Neonates, Infants, and Children ≤2 Years of Age: A Comparison of the Predictive Performance of 4 Allometric Models.
Mahmood I
J Clin Pharmacol; 2016 Jun; 56(6):733-9. PubMed ID: 26437918
[TBL] [Abstract][Full Text] [Related]
3. The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years.
Edginton AN; Shah B; Sevestre M; Momper JD
Clin Pharmacokinet; 2013 Aug; 52(8):693-703. PubMed ID: 23588537
[TBL] [Abstract][Full Text] [Related]
4. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007.
Momper JD; Mulugeta Y; Green DJ; Karesh A; Krudys KM; Sachs HC; Yao LP; Burckart GJ
JAMA Pediatr; 2013 Oct; 167(10):926-32. PubMed ID: 23921678
[TBL] [Abstract][Full Text] [Related]
5. Prediction of Clearance in Neonates and Infants (≤ 3 Months of Age) for Drugs That Are Glucuronidated: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling.
Mahmood I; Ahmad T; Mansoor N; Sharib SM
J Clin Pharmacol; 2017 Apr; 57(4):476-483. PubMed ID: 27704554
[TBL] [Abstract][Full Text] [Related]
6. Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry.
Sinha VK; Vaarties K; De Buck SS; Fenu LA; Nijsen M; Gilissen RA; Sanderson W; Van Uytsel K; Hoeben E; Van Peer A; Mackie CE; Smit JW
Clin Pharmacokinet; 2011 May; 50(5):307-18. PubMed ID: 21456631
[TBL] [Abstract][Full Text] [Related]
7. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.
Ring BJ; Chien JY; Adkison KK; Jones HM; Rowland M; Jones RD; Yates JW; Ku MS; Gibson CR; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
J Pharm Sci; 2011 Oct; 100(10):4090-110. PubMed ID: 21541938
[TBL] [Abstract][Full Text] [Related]
8. A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling for the Prediction of Drug Clearance From Neonates to Adolescents.
Mahmood I; Tegenge MA
J Clin Pharmacol; 2019 Feb; 59(2):189-197. PubMed ID: 30192373
[TBL] [Abstract][Full Text] [Related]
9. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
Vuppugalla R; Marathe P; He H; Jones RD; Yates JW; Jones HM; Gibson CR; Chien JY; Ring BJ; Adkison KK; Ku MS; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
J Pharm Sci; 2011 Oct; 100(10):4111-26. PubMed ID: 21480234
[TBL] [Abstract][Full Text] [Related]
10. Multistep Unified Models Using Prior Knowledge for the Prediction of Drug Clearance in Neonates and Infants.
Tegenge MA; Mahmood I; Jiang Z; Forshee R
J Clin Pharmacol; 2018 Jul; 58(7):877-884. PubMed ID: 29489016
[TBL] [Abstract][Full Text] [Related]
11. Prediction of clearance and volume of distribution in the obese from normal weight subjects: an allometric approach.
Mahmood I
Clin Pharmacokinet; 2012 Aug; 51(8):527-42. PubMed ID: 22671778
[TBL] [Abstract][Full Text] [Related]
12. Prediction of drug clearance in children.
Foissac F; Bouazza N; Valade E; De Sousa Mendes M; Fauchet F; Benaboud S; Hirt D; Tréluyer JM; Urien S
J Clin Pharmacol; 2015 Jul; 55(7):739-47. PubMed ID: 25721251
[TBL] [Abstract][Full Text] [Related]
13. An Update on the Use of Allometric and Other Scaling Methods to Scale Drug Clearance in Children: Towards Decision Tables.
van Rongen A; Krekels EH; Calvier EA; de Wildt SN; Vermeulen A; Knibbe CA
Expert Opin Drug Metab Toxicol; 2022 Feb; 18(2):99-113. PubMed ID: 35018879
[TBL] [Abstract][Full Text] [Related]
14. Misconceptions and issues regarding allometric scaling during the drug development process.
Mahmood I
Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):843-854. PubMed ID: 29999428
[TBL] [Abstract][Full Text] [Related]
15. Prediction of glucuronidated drug clearance in pediatrics (≤5 years): An allometric approach.
Mahmood I
Eur J Drug Metab Pharmacokinet; 2015 Mar; 40(1):53-9. PubMed ID: 24519316
[TBL] [Abstract][Full Text] [Related]
16. Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?
Calvier EA; Krekels EH; Välitalo PA; Rostami-Hodjegan A; Tibboel D; Danhof M; Knibbe CA
Clin Pharmacokinet; 2017 Mar; 56(3):273-285. PubMed ID: 27510367
[TBL] [Abstract][Full Text] [Related]
17. Prediction of drug clearance in children: impact of allometric exponents, body weight, and age.
Mahmood I
Ther Drug Monit; 2007 Jun; 29(3):271-8. PubMed ID: 17529882
[TBL] [Abstract][Full Text] [Related]
18. Model-Aided Adults-to-Children Pharmacokinetic Extrapolation and Empirical Body Size-Based Dosing Exploration for Therapeutic Monoclonal Antibodies-Is Allometry a Reasonable Choice?
Xu Y; Langevin BA; Zhou H; Xu Z
J Clin Pharmacol; 2020 Dec; 60(12):1573-1584. PubMed ID: 32578225
[TBL] [Abstract][Full Text] [Related]
19. Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization.
Zheng L; Xu M; Tang SW; Song HX; Jiang XH; Wang L
Pharm Res; 2019 Oct; 36(12):171. PubMed ID: 31654287
[TBL] [Abstract][Full Text] [Related]
20. Predicting oral clearance in humans: how close can we get with allometry?
Sinha VK; De Buck SS; Fenu LA; Smit JW; Nijsen M; Gilissen RA; Van Peer A; Lavrijsen K; Mackie CE
Clin Pharmacokinet; 2008; 47(1):35-45. PubMed ID: 18076217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
